Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2016
Price : $35 *
At a glance
- Drugs Immunoglobulin G (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms PREDICT
- Sponsors Octapharma
- 01 Oct 2016 Status changed from active, no longer recruiting to completed.
- 18 Dec 2013 Trial design has been presented at the European Charcot Foundation annual meeting, according to an Octapharma media release.
- 18 Dec 2013 The first 2 patients have been enrolled in Bulgaria, according to an Octapharma media release.